Liberty Health Sciences to be exclusive distributor of Isodiol International products throughout Florida and Massachusetts

Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) is pleased to announce that it has signed a licensing agreement with Isodiol International Inc., a pioneer in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer goods, to supply a complementary package of medical cannabis products to patients in Florida and Massachusetts.

“Liberty is proud to team up with Isodiol, a company renowned for its ability to process and extract high purity CBD on an industrial scale,” stated George Scorsis, Director and CEO of Liberty. “We are dedicated to providing all our patients around Massachusetts and Florida with an extensive selection of medical cannabis and derivative products. Isodiol is an excellent addition to our rapidly expanding portfolio of celebrated brands as we continue to execute on our aggressive growth strategy to roll out dispensary places and product offerings across Florida and Massachusetts.”

The Isodiol branded goods will be available for sale through Liberty’s Cannabis Education Centers. The Company continues to add an range of products and brands which allow Liberty to cover the needs of all patients in many different forms. This exciting new product line will complement Liberty’s expanding lineup of brands to be offered to Florida and Massachusetts patients, such as Aphria, Solei, Mary’s Medicinals and incredibles. The arrangement with Isodiol allows Liberty to license and create the following products:

  • Isodiol’s BIOACTIVE CBD
  • Isodiol’s CannaCeuticals
  • Isodiol’s IsoDerm
  • Isodiol’s IsoSport products
  • Isodiol’s Rapid Cream
  • Isodiol’s Rapid Patch
  • Isodiol’s Pot-O-Coffee

“Isodiol is excited to partner with a company that’s equally dedicated to deliver health and wellness to customers around the globe,” said CEO of Isodiol, Marcos Agramont. “Florida and Massachusetts will further expand the marketplace for Isodiol and we look forward to establishing a long-term partnership with Liberty with further expansion later on.”

Possessing the unique capability to export its pharmaceuticals grade, organic hemp derived Cannabidiol (CBD) product technology anywhere in the world, Isodiol is prepared to satisfy the United States’ rapidly increasing requirement for the busy CBD material working with a partner such as Liberty. This worldwide distribution capability was secured on April 26, 2018, when Isodiol’s wholly owned subsidiary, BSPG Laboratories, LTD., obtained cGMP compliance status from United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA), for the manufacture of the active substance Cannabidiol using their proprietary technology.

The closing of this agreement is subject to receipt of all required approvals from the Florida Department of Health, Office of Medical Marijuana Use and the Commonwealth of Massachusetts, Medical Use of Marijuana Program or the Massachusetts Cannabis Control Commission.

About Liberty Health Sciences Inc..

Liberty’s stringent investment criteria for expansion maximizes returns to shareholders, while focusing on important near- and – mid-term opportunities.  Liberty has an extensive history in highly regulated industries, with experience in becoming a low-cost producer.  Liberty leverages commercial greenhouse knowledge to deliver high quality, clean and safe pharmaceutical grade cannabis to patients.

To find out more, please visit libertyheathsciences.com

SOURCE

Published at Wed, 30 May 2018 14:51:43 +0000

Posted in: News

Comments are closed.